GI Dynamics appoints Mark Twyman CCO
This article was originally published in Scrip
GI Dynamics, a company developing non-surgical approaches for treating type 2 diabetes and obesity, has appointed Mark Twyman to the newly created role of chief commercial officer, reporting to Stuart Randle, president and CEO. Mr Twyman has previously served as companies including MedImmune and Merck, and most recently served as senior vice-president and general manager at Genzyme Biosurgery.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.